167 related articles for article (PubMed ID: 16500583)
1. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction.
Wagner DR; Delagardelle C; Ernens I; Rouy D; Vaillant M; Beissel J
J Card Fail; 2006 Feb; 12(1):66-72. PubMed ID: 16500583
[TBL] [Abstract][Full Text] [Related]
2. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function.
Orn S; Manhenke C; Squire IB; Ng L; Anand I; Dickstein K
J Card Fail; 2007 Dec; 13(10):843-9. PubMed ID: 18068618
[TBL] [Abstract][Full Text] [Related]
3. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
4. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
[TBL] [Abstract][Full Text] [Related]
5. N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction.
Tziakas DN; Chalikias GK; Hatzinikolaou EI; Stakos DA; Tentes IK; Kortsaris A; Hatseras DI; Kaski JC
Am J Cardiol; 2005 Jul; 96(1):31-4. PubMed ID: 15979428
[TBL] [Abstract][Full Text] [Related]
6. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
7. Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction.
Matsunaga T; Abe N; Kameda K; Hagii J; Fujita N; Onodera H; Kamata T; Ishizaka H; Hanada H; Osanai T; Okumura K
Int J Cardiol; 2005 Nov; 105(2):203-8. PubMed ID: 16243114
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of soluble Fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction.
Onoue K; Uemura S; Takeda Y; Somekawa S; Iwama H; Nishida T; Morikawa Y; Nakagawa H; Tsutsumi T; Sung JH; Takemoto Y; Soeda T; Okayama S; Ishigami K; Kawata H; Horii M; Nakajima T; Saito Y
Am J Cardiol; 2009 Dec; 104(11):1478-83. PubMed ID: 19932778
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
[TBL] [Abstract][Full Text] [Related]
10. Sudden cardiovascular death following myocardial infarction: the importance of left ventricular systolic dysfunction and congestive heart failure.
Abildstrom SZ; Ottesen MM; Rask-Madsen C; Andersen PK; Rosthøj S; Torp-Pedersen C; Køber L
Int J Cardiol; 2005 Sep; 104(2):184-9. PubMed ID: 16168812
[TBL] [Abstract][Full Text] [Related]
11. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes.
Chong AY; Freestone B; Patel J; Lim HS; Hughes E; Blann AD; Lip GY
Am J Cardiol; 2006 Mar; 97(5):671-5. PubMed ID: 16490435
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis.
Jordán A; Roldán V; García M; Monmeneu J; de Burgos FG; Lip GY; Marín F
J Intern Med; 2007 Sep; 262(3):385-92. PubMed ID: 17697160
[TBL] [Abstract][Full Text] [Related]
13. Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18.
Wylie JV; Murphy SA; Morrow DA; de Lemos JA; Antman EM; Cannon CP
Am Heart J; 2004 Jul; 148(1):173-80. PubMed ID: 15215808
[TBL] [Abstract][Full Text] [Related]
14. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure.
Lamblin N; Mouquet F; Hennache B; Dagorn J; Susen S; Bauters C; de Groote P
Eur Heart J; 2005 Nov; 26(21):2245-50. PubMed ID: 16183690
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction.
Yasuda S; Miyazaki S; Kinoshita H; Nagaya N; Kanda M; Goto Y; Nonogi H
Clin Sci (Lond); 2007 Jan; 112(1):43-9. PubMed ID: 16939410
[TBL] [Abstract][Full Text] [Related]
16. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction.
Nakaya R; Uzui H; Shimizu H; Nakano A; Mitsuke Y; Yamazaki T; Ueda T; Lee JD
Int J Cardiol; 2005 Oct; 105(1):67-73. PubMed ID: 16207547
[TBL] [Abstract][Full Text] [Related]
17. Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy.
Ohtsuka T; Nishimura K; Kurata A; Ogimoto A; Okayama H; Higaki J
J Card Fail; 2007 Nov; 13(9):752-8. PubMed ID: 17996824
[TBL] [Abstract][Full Text] [Related]
18. Cytokine activation and disease progression in patients with stable moderate chronic heart failure.
Tanner H; Mohacsi P; Fuller-Bicer GA; Rieben R; Meier B; Hess O; Hullin R
J Heart Lung Transplant; 2007 Jun; 26(6):622-9. PubMed ID: 17543787
[TBL] [Abstract][Full Text] [Related]
19. Clinical and prognostic value of advanced glycation end-products in chronic heart failure.
Hartog JW; Voors AA; Schalkwijk CG; Scheijen J; Smilde TD; Damman K; Bakker SJ; Smit AJ; van Veldhuisen DJ
Eur Heart J; 2007 Dec; 28(23):2879-85. PubMed ID: 17986469
[TBL] [Abstract][Full Text] [Related]
20. Head-to-head comparison of BNP and IL-6 as markers of clinical and experimental heart failure: Superiority of BNP.
Birner CM; Ulucan C; Fredersdorf S; Rihm M; Löwel H; Stritzke J; Schunkert H; Hengstenberg C; Holmer S; Riegger G; Luchner A
Cytokine; 2007 Nov; 40(2):89-97. PubMed ID: 17920926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
